<p>根據 MarketBeat.com 的報道，覆蓋該股票的六位分析師給 Tourmaline Bio, Inc. (NASDAQ: TRML) 給予了&#34;買入&#34;的一致評級。六位研究分析師中有六位給予了買入評級。過去一年更新了對該股票的覆蓋的分析師中，平均十二個月的目標股價為 61.80 美元。</p>
<p>獲取 <strong>Tourmaline Bio</strong> 的警報：</p>
<ul>
<li>百時美施貴寶的大舉購買：在兩筆生物科技交易中共計 181 億美元</li>
</ul>
<p>另外，HC Wainwright 重申了對 Tourmaline Bio 的&#34;買入&#34;評級，並設定了 48.00 美元的價格目標。</p>
<p><strong>查看我們對 Tourmaline Bio 的最新股票分析</strong></p>
<h2>內部買賣情況</h2>
<p>相關新聞中，首席執行官 Sandeep Chidambar Kulkarni 於 8 月 16 日星期五以 13.79 美元的平均價格每股購買了 5,221 股公司股票，總交易額為 71,997.59 美元。購買後，首席執行官現在持有公司 5,221 股股票，價值 71,997.59 美元。這一收購交易已在提交給美國證券交易委員會的文件中披露，可通過此鏈接查看。公司股份的 11.02% 歸公司內部人士所有。</p>
<h2>對 Tourmaline Bio 的對沖基金看法</h2>
<p>一些對沖基金和其他機構投資者最近調整了他們對該公司的持股。BNP Paribas Financial Markets 在第一季度購入了一筆價值 31,000 美元的 Tourmaline Bio 股票。Quest Partners LLC 在第二季度增持了 134.0% 的 Tourmaline Bio 股票。中國通用資產管理有限公司在第一季度增持了 109.5% 的 Tourmaline Bio 股票。Denali Advisors LLC 在第一季度以 128,000 美元的價格獲得了 Tourmaline Bio 的新頭寸。最後，Janus Henderson Group PLC 在第一季度以約 266,000 美元的價格獲得了 Tourmaline Bio 的新頭寸。公司股份的 91.89% 歸機構投資者所有。</p>
<h2>Tourmaline Bio 股價上漲 8.2%</h2>
<p>週五，納斯達克 TRML 的股價開盤價為 19.27 美元。Tourmaline Bio 的一年最低價為 9.18 美元，最高價為 48.31 美元。該股的五十天簡單移動平均價為 15.62 美元，兩百天簡單移動平均價為 19.04 美元。該公司的市值為 4.9408 億美元，市盈率為-2.96，貝塔係數為 2.31。</p>
<p>Tourmaline Bio (NASDAQ: TRML) 在 8 月 8 日星期四發佈了季度財報。公司報告該季度每股收益為-0.68 美元，超過了每股收益為-0.72 美元的共識預期 0.04 美元。分析師預測 Tourmaline Bio 今年將實現-3.12 美元的每股收益。</p>
<h2>Tourmaline Bio 公司簡介</h2>
<p>Tourmaline Bio, Inc 是一家臨牀生物技術公司，致力於為患有改變生活的免疫和炎症性疾病的患者開發藥物。公司開發了 TOUR006，一種人源抗 IL-6 單克隆抗體，選擇性結合白細胞介素-6，這是許多自身免疫和炎症性疾病發病機制中的關鍵促炎細胞因子。</p>
<h2>精選故事</h2>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJNTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJNTA"/></p>
<p><em>此即時新聞警報由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 2024 年 9 月的第一加密貨幣（來自 Crypto 101 Media）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTQ1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTQ1"/></p>
<h2>現在是否值得投資 1000 美元到 Tourmaline Bio？</h2>
<p>在考慮投資 Tourmaline Bio 之前，您會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而 Tourmaline Bio 不在名單上。</p>
<p>雖然 Tourmaline Bio 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

TRML

<p>Tourmaline Bio（納斯達克股票代碼：TRML）獲得了六位分析師一致的 “買入” 評級，平均目標股價為 0.80 美元。首席執行官 Sandeep Chidambar Kulkarni 最近以每股 0.79 美元的價格購買了 5,221 股股票。機構投資者持有該股的 91.89%。該股最近上漲了 8.2%，報價為 0.27 美元，一年內的交易範圍為 0.18 美元至 0.31 美元。Tourmaline Bio 專注於開發治療免疫和炎症性疾病的療法，包括其單克隆抗體 TOUR006</p>

<p>Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given a consensus rating of &#34;Buy&#34; by the six analysts that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $61.80.</p>
<div class="lb-trans"><p>根據 MarketBeat.com 的報道，覆蓋該股票的六位分析師給 Tourmaline Bio, Inc. (NASDAQ: TRML) 給予了&#34;買入&#34;的一致評級。六位研究分析師中有六位給予了買入評級。過去一年更新了對該股票的覆蓋的分析師中，平均十二個月的目標股價為 61.80 美元。</p>
</div><p>Get <strong>Tourmaline Bio</strong> alerts:</p>
<ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Tourmaline Bio</strong> 的警報：</p>
<ul>
<li>百時美施貴寶的大舉購買：在兩筆生物科技交易中共計 181 億美元</li>
</ul>
</div><p>Separately, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $48.00 price objective on shares of Tourmaline Bio in a research report on Monday, August 12th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 重申了對 Tourmaline Bio 的&#34;買入&#34;評級，並設定了 48.00 美元的價格目標。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Tourmaline Bio</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Tourmaline Bio 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><p>In related news, CEO Sandeep Chidambar Kulkarni bought 5,221 shares of the firm's stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.79 per share, for a total transaction of $71,997.59. Following the purchase, the chief executive officer now owns 5,221 shares in the company, valued at $71,997.59. The acquisition was disclosed in a filing with the SEC, which is available through this link. 11.02% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>相關新聞中，首席執行官 Sandeep Chidambar Kulkarni 於 8 月 16 日星期五以 13.79 美元的平均價格每股購買了 5,221 股公司股票，總交易額為 71,997.59 美元。購買後，首席執行官現在持有公司 5,221 股股票，價值 71,997.59 美元。這一收購交易已在提交給美國證券交易委員會的文件中披露，可通過此鏈接查看。公司股份的 11.02% 歸公司內部人士所有。</p>
</div><h2>Hedge Funds Weigh In On Tourmaline Bio</h2>
<div class="lb-trans"><h2>對 Tourmaline Bio 的對沖基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in Tourmaline Bio in the 1st quarter worth $31,000. Quest Partners LLC grew its holdings in Tourmaline Bio by 134.0% in the second quarter. Quest Partners LLC now owns 3,822 shares of the company's stock worth $49,000 after purchasing an additional 2,189 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Tourmaline Bio by 109.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 4,939 shares of the company's stock valued at $113,000 after buying an additional 2,582 shares during the last quarter. Denali Advisors LLC acquired a new position in Tourmaline Bio during the first quarter valued at $128,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Tourmaline Bio in the first quarter worth about $266,000. 91.89% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近調整了他們對該公司的持股。BNP Paribas Financial Markets 在第一季度購入了一筆價值 31,000 美元的 Tourmaline Bio 股票。Quest Partners LLC 在第二季度增持了 134.0% 的 Tourmaline Bio 股票。中國通用資產管理有限公司在第一季度增持了 109.5% 的 Tourmaline Bio 股票。Denali Advisors LLC 在第一季度以 128,000 美元的價格獲得了 Tourmaline Bio 的新頭寸。最後，Janus Henderson Group PLC 在第一季度以約 266,000 美元的價格獲得了 Tourmaline Bio 的新頭寸。公司股份的 91.89% 歸機構投資者所有。</p>
</div><h2>Tourmaline Bio Trading Up 8.2 %</h2>
<div class="lb-trans"><h2>Tourmaline Bio 股價上漲 8.2%</h2>
</div><p>Shares of NASDAQ TRML opened at $19.27 on Friday. Tourmaline Bio has a 1-year low of $9.18 and a 1-year high of $48.31. The stock has a fifty day simple moving average of $15.62 and a two-hundred day simple moving average of $19.04. The firm has a market cap of $494.08 million, a price-to-earnings ratio of -2.96 and a beta of 2.31.</p>
<div class="lb-trans"><p>週五，納斯達克 TRML 的股價開盤價為 19.27 美元。Tourmaline Bio 的一年最低價為 9.18 美元，最高價為 48.31 美元。該股的五十天簡單移動平均價為 15.62 美元，兩百天簡單移動平均價為 19.04 美元。該公司的市值為 4.9408 億美元，市盈率為-2.96，貝塔係數為 2.31。</p>
</div><p>Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.04. Analysts forecast that Tourmaline Bio will post -3.12 EPS for the current year.</p>
<div class="lb-trans"><p>Tourmaline Bio (NASDAQ: TRML) 在 8 月 8 日星期四發佈了季度財報。公司報告該季度每股收益為-0.68 美元，超過了每股收益為-0.72 美元的共識預期 0.04 美元。分析師預測 Tourmaline Bio 今年將實現-3.12 美元的每股收益。</p>
</div><h2>Tourmaline Bio Company Profile (Get Free Report</h2>
<div class="lb-trans"><h2>Tourmaline Bio 公司簡介</h2>
</div><p>Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.</p>
<div class="lb-trans"><p>Tourmaline Bio, Inc 是一家臨牀生物技術公司，致力於為患有改變生活的免疫和炎症性疾病的患者開發藥物。公司開發了 TOUR006，一種人源抗 IL-6 單克隆抗體，選擇性結合白細胞介素-6，這是許多自身免疫和炎症性疾病發病機制中的關鍵促炎細胞因子。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Tourmaline Bio</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Can Celsius Stock Rebound? Analysts See 74% Upside Potential</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>Kroger Stock is a Win-Win for Buy-and-Hold Investors</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>MarketBeat Week in Review – 9/9 - 9/13</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJNTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TRML"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ The #1 Altcoin for September 2024 (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 2024 年 9 月的第一加密貨幣（來自 Crypto 101 Media）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTQ1" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9545&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Tourmaline Bio right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元到 Tourmaline Bio？</h2>
</div><p>Before you consider Tourmaline Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Tourmaline Bio 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tourmaline Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票...而 Tourmaline Bio 不在名單上。</p>
</div><p>While Tourmaline Bio currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tourmaline Bio 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Tourmaline Bio, Inc.（納斯達克股票代碼：TRML）獲得分析師的平均 “買入” 評級